Fate Therapeutics (FATE) Competitors $1.17 -0.08 (-6.40%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.25 +0.08 (+6.75%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. MNMD, DNA, ARVN, TSHA, CGEM, ETON, ALT, SANA, MGTX, and MAZEShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Mind Medicine (MindMed) (MNMD), Ginkgo Bioworks (DNA), Arvinas (ARVN), Taysha Gene Therapies (TSHA), Cullinan Therapeutics (CGEM), Eton Pharmaceuticals (ETON), Altimmune (ALT), Sana Biotechnology (SANA), MeiraGTx (MGTX), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Mind Medicine (MindMed) Ginkgo Bioworks Arvinas Taysha Gene Therapies Cullinan Therapeutics Eton Pharmaceuticals Altimmune Sana Biotechnology MeiraGTx Maze Therapeutics Mind Medicine (MindMed) (NASDAQ:MNMD) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership. Which has higher valuation and earnings, MNMD or FATE? Mind Medicine (MindMed) has higher earnings, but lower revenue than Fate Therapeutics. Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMind Medicine (MindMed)N/AN/A-$95.73M-$1.29-5.38Fate Therapeutics$13.34M10.06-$160.93M-$1.49-0.79 Do analysts rate MNMD or FATE? Mind Medicine (MindMed) presently has a consensus price target of $25.11, suggesting a potential upside of 261.83%. Fate Therapeutics has a consensus price target of $4.14, suggesting a potential upside of 254.09%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than Fate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 4 Strong Buy rating(s) 3.31Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22 Is MNMD or FATE more profitable? Mind Medicine (MindMed) has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat Mind Medicine (MindMed)'s return on equity.Company Net Margins Return on Equity Return on Assets Mind Medicine (MindMed)N/A -47.56% -35.55% Fate Therapeutics -1,325.43%-45.88%-33.95% Does the media prefer MNMD or FATE? In the previous week, Fate Therapeutics had 11 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 20 mentions for Fate Therapeutics and 9 mentions for Mind Medicine (MindMed). Mind Medicine (MindMed)'s average media sentiment score of 1.23 beat Fate Therapeutics' score of 0.64 indicating that Mind Medicine (MindMed) is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mind Medicine (MindMed) 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in MNMD or FATE? Fate Therapeutics received 424 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 93.44% of users gave Mind Medicine (MindMed) an outperform vote while only 67.27% of users gave Fate Therapeutics an outperform vote. CompanyUnderperformOutperformMind Medicine (MindMed)Outperform Votes5793.44% Underperform Votes46.56%Fate TherapeuticsOutperform Votes48167.27% Underperform Votes23432.73% Do insiders & institutionals believe in MNMD or FATE? 27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 2.5% of Mind Medicine (MindMed) shares are owned by insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, MNMD or FATE? Mind Medicine (MindMed) has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. SummaryMind Medicine (MindMed) beats Fate Therapeutics on 10 of the 18 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$134.09M$2.93B$5.37B$8.38BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.7130.5026.8419.71Price / Sales10.06400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book0.313.286.794.50Net Income-$160.93M-$72.17M$3.23B$248.18M7 Day Performance21.88%4.28%4.07%1.14%1 Month Performance-6.40%7.62%12.52%15.20%1 Year Performance-68.38%-28.15%16.83%6.56% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.3512 of 5 stars$1.17-6.4%$4.14+254.1%-68.4%$134.09M$13.34M-0.71550Gap UpMNMDMind Medicine (MindMed)2.2643 of 5 stars$6.45+4.9%$25.11+289.3%-16.8%$486.12MN/A-2.8540Positive NewsDNAGinkgo Bioworks1.1157 of 5 stars$8.30+6.9%$4.58-44.9%N/A$481.62M$237.42M-0.63640Positive NewsARVNArvinas3.7269 of 5 stars$6.52-1.4%$20.91+220.7%-82.0%$475.90M$426.90M-2.35420TSHATaysha Gene Therapies3.0123 of 5 stars$2.32+8.9%$6.63+185.6%+0.0%$475.73M$8.33M3.68180Earnings ReportAnalyst RevisionGap DownCGEMCullinan Therapeutics2.3156 of 5 stars$7.91+4.9%$32.00+304.6%-66.0%$466.81MN/A-2.7930ETONEton Pharmaceuticals2.3916 of 5 stars$17.35+3.3%$27.67+59.5%+463.8%$465.29M$39.01M-78.8620Positive NewsAnalyst RevisionHigh Trading VolumeALTAltimmune2.6242 of 5 stars$6.01+7.5%$20.20+236.1%-27.4%$462.85M$20,000.00-3.8850Analyst RevisionGap DownSANASana Biotechnology2.447 of 5 stars$2.00+9.9%$10.80+440.0%-76.4%$450.95MN/A-1.43380High Trading VolumeMGTXMeiraGTx4.572 of 5 stars$5.62+3.7%$24.50+335.9%-3.6%$449.33M$33.28M-4.64300Analyst RevisionMAZEMaze TherapeuticsN/A$10.13+5.3%$25.67+153.4%N/A$443.65M$167.50M0.00121Gap Up Related Companies and Tools Related Companies Mind Medicine (MindMed) Alternatives Ginkgo Bioworks Alternatives Arvinas Alternatives Taysha Gene Therapies Alternatives Cullinan Therapeutics Alternatives Eton Pharmaceuticals Alternatives Altimmune Alternatives Sana Biotechnology Alternatives MeiraGTx Alternatives Maze Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FATE Stock Free FATE Stock Alerts